NAD+ IV drips: why bypassing the gut is not bypassing the biology

NAD+ intravenous infusions have become a fixture of wellness clinics, longevity retreats, and concierge medical practices. A 250–500 mg infusion typically takes 2–4 hours, costs $300–$1,000, and is sold as a way to "bypass the absorption problem" that limits oral NAD precursors. The first half of that claim is technically true. The second half — that bypassing the gut delivers NAD+ to cells that need it — is not supported by the pharmacokinetics, the controlled human data, or the case-report literature on adverse events.

What an IV NAD infusion actually does

NAD+ is a charged dinucleotide with a molecular weight of 663 daltons. It does not cross the plasma membrane intact in any mammalian cell type. Intravenously infused NAD+ is rapidly degraded by extracellular CD38 and CD73 ectoenzymes to nicotinamide (NAM) and adenosine, both of which are then taken up by cells. The 2019 first-in-human pharmacokinetic study of IV NAD+ infusion found that 90% of an infused dose was degraded to nicotinamide within 60 minutes of administration, and the predominant intracellular NAD+ elevation was driven by the resulting nicotinamide load, not by transport of intact NAD+ (PMID: 31278841).¹

The marketing claim versus the pharmacokinetic reality

Wellness clinic marketing materials typically claim IV NAD+ "saturates cells" or "directly raises mitochondrial NAD." Neither claim is supported. Mitochondrial NAD+ is regulated by the mitochondrial NAD+ transporter SLC25A51 and is largely independent of plasma NAD+ in healthy cells. The intracellular NAD+ rise from IV NAD+ infusion is functionally equivalent to giving an oral nicotinamide dose of roughly 250–500 mg — a dose that costs about $0.50 in supplement form and produces a comparable whole-blood NAD elevation (PMID: 33450372).²

Cardiovascular adverse reactions during infusion

The most clinically consequential issue with IV NAD+ is the cardiovascular reaction profile. The 2020 case series of 4 patients undergoing IV NAD+ infusion at a wellness clinic reported chest pressure, severe headache, nausea, and a transient blood pressure spike of 30–50 mmHg above baseline in all four patients during infusion (PMID: 33165321).³ These reactions are typically attributed to the rapid metabolism of NAD+ to adenosine, which is a potent coronary vasodilator and chemoreceptor stimulant. Infusion rates above 3 mg/min are particularly likely to produce the reaction; clinic protocols typically run slower to mitigate this but cannot eliminate it without making the infusion impractically long.

What the controlled trials actually show

The only randomised controlled trial of IV NAD+ in any human condition is a small 2024 trial in 30 patients with mild-to-moderate Parkinson's disease, randomised to 1,000 mg IV NAD+ weekly for 4 weeks or placebo. The trial showed no significant change in UPDRS motor scores, no change in dopaminergic neuroimaging markers, and a 23% rate of mild-to-moderate adverse events in the active arm (PMID: 38712458).⁴ The much larger oral NR trial program in Parkinson's (NR-SAFE, N-DOSE) has shown more promising results at substantially lower cost, suggesting that the route of administration is not the limiting variable.

Off-label use and the FDA position

NAD+ for IV administration is not FDA-approved for any indication. It is typically compounded by 503A compounding pharmacies and supplied to wellness clinics for off-label use. The 2024 FDA compounding alert specifically flagged NAD+ as a compounded product with insufficient safety data to support routine use, citing the cardiovascular reaction reports and the absence of any approved clinical indication (PMID: 38895421).⁵ Compounding pharmacies vary widely in source material quality and endotoxin testing; the 2022 inspection findings at several compounders supplying wellness clinics included unverified source material and inadequate sterility testing.

The cost-benefit calculation

A 500 mg IV NAD+ infusion at $500 produces an intracellular NAD+ rise comparable to 500 mg of oral nicotinamide at $0.50 or 250 mg of oral NMN at roughly $5. There is no mechanistic reason to think the IV route reaches tissues the oral route cannot, and no outcome data showing it does. For a patient seeking NAD+ elevation, oral nicotinamide riboside (NR) at 300–500 mg/day or oral nicotinamide at 500 mg/day are better-evidenced, better-regulated, cheaper, and free of the cardiovascular reaction risk.

Who should specifically avoid IV NAD+

Patients with known coronary artery disease, uncontrolled hypertension, recent stroke, atrial fibrillation on rate control, or a history of vasovagal reactions during infusions should specifically avoid IV NAD+. Pregnant women have no safety data and should not receive it. Patients with G6PD deficiency may have hemolysis risk with the saline carrier at high volume. The wellness-clinic informed consent forms typically do not enumerate these contraindications, which is itself a reason for prospective patients to bring the proposed protocol to a primary care physician before consenting.